L-Threonine for Health & Longevity

Evidence Review created on 05/06/2026 using AI4L / Opus 4.7

Also known as: Threonine, Thr, T, (2S,3R)-2-Amino-3-hydroxybutanoic acid, L-Thr

Motivation

L-Threonine is one of the building blocks of protein that the body cannot make on its own and must obtain from food, where its primary biological role is incorporation into the proteins that make up nearly every tissue in the body. It is found in a wide range of foods, including meat, dairy, eggs, beans, and grains, and is also sold as a stand-alone supplement in capsule and powder form for those seeking to add more than what diet alone provides.

Although a single gram or so per day from a normal diet meets baseline needs, supplemental L-Threonine has been studied for muscle spasticity, gut barrier health, and, more recently, healthspan signals in laboratory animals. Reports linking L-Threonine to delayed aging in nematodes have attracted renewed attention, even as direct human longevity trials remain absent.

This review examines what is known about L-Threonine for health- and longevity-oriented adults: where supplementation has supportive controlled-trial data, where claims rely on animal models or theoretical mechanisms, and how dose, form, and individual context shape the risk-benefit picture.

Benefits - Risks - Protocol - Conclusion

Grokipedia

Threonine

A comprehensive entry covering L-Threonine’s chemistry as an essential amino acid, its role as a precursor to glycine and serine, its contribution to collagen and elastin synthesis, the WHO-FAO-UNU adult requirement of approximately 15 mg/kg/day, and its dietary distribution across animal and plant protein sources.

Examine

No dedicated Examine.com article for L-Threonine was found.

ConsumerLab

No dedicated ConsumerLab.com article for L-Threonine was found.

Systematic Reviews

This section presents the most relevant systematic reviews and meta-analyses identified through PubMed that bear on L-Threonine in human supplementation contexts.

Anti-spasticity agents for multiple sclerosis - Shakespeare et al., 2000

A Cochrane systematic review of 23 placebo-controlled and 13 comparative RCTs (randomized controlled trials, the gold-standard study design that randomly assigns participants to intervention or control) of antispasticity agents in MS (multiple sclerosis, an autoimmune disease that damages the myelin sheath surrounding nerve fibers), including threonine, baclofen, dantrolene, tizanidine, botulinum toxin, vigabatrin, and prazepam; concludes that the absolute and comparative efficacy of antispasticity agents — threonine included — is poorly documented and that no recommendations can be made on the strength of available trials.
Symptomatic treatments for amyotrophic lateral sclerosis/motor neuron disease - Ng et al., 2017

A Cochrane overview of nine systematic reviews covering symptomatic treatments for ALS (amyotrophic lateral sclerosis, a progressive neurodegenerative disease affecting motor neurons in the brain and spinal cord) including L-Threonine for cramps and spasticity; the review classifies L-Threonine effects as “uncertain” because evidence is very low quality or numerical outcome data are not reported, and groups it with other agents that have not demonstrated reliable benefit.
Clinical effectiveness of oral treatments for spasticity in multiple sclerosis: a systematic review - Paisley et al., 2002

A systematic review of oral antispasticity agents in MS that evaluates baclofen, dantrolene, tizanidine, diazepam, gabapentin, and threonine; concludes that the single available RCT of threonine does not support its effectiveness for clinically meaningful spasticity outcomes, while baclofen, tizanidine, and diazepam are effective on clinical measures without consistent functional improvement.

Note: PubMed contains no systematic reviews or meta-analyses of L-Threonine for healthspan, longevity, gut function, or other primary health-and-longevity indications in humans as of the date of this review. The three reviews above all examine L-Threonine in the narrow MS/ALS spasticity context. The 2025 Matsumoto safety RCT is a primary trial, not a systematic review, and is therefore cited under Mechanism of Action and Risks rather than here. This unusually thin systematic-review base reflects the absence of large-scale clinical research programs targeting L-Threonine outside the spasticity literature of the 1990s and early 2000s.

Mechanism of Action

L-Threonine is one of the nine essential amino acids and is incorporated into virtually every protein in the body. Beyond its structural role, several distinct biological pathways are relevant to supplementation.

Glycine precursor and inhibitory neurotransmission. L-Threonine crosses the blood-brain barrier via the LNAA (large neutral amino acid, a shared transport system that moves several similarly-sized amino acids across cell membranes) transporter and can be converted to glycine through the enzyme threonine dehydrogenase or via serine hydroxymethyltransferase activity. Glycine is the primary inhibitory neurotransmitter of the spinal cord motor reflex arc. Increased threonine availability is hypothesized to enhance glycinergic postsynaptic inhibition and dampen exaggerated motor reflexes — the mechanistic rationale for the antispasticity trials of the 1990s.

Mucin biosynthesis and gut barrier integrity. L-Threonine is a major structural component of mucin (a glycoprotein that forms the protective mucus gel covering epithelial surfaces, particularly in the intestine) — mucins contain among the highest threonine content of any class of secreted proteins, with as much as 28% to 35% threonine residues in some mucin domains. Roughly 40–60% of dietary threonine is extracted by the gut on first pass for mucin synthesis. Threonine availability is rate-limiting for goblet-cell mucin output in animal models; depletion impairs mucus barrier function and increases paracellular intestinal permeability.

Glucogenic and ketogenic metabolism. L-Threonine is both glucogenic (can be converted to glucose-precursor intermediates via 2-amino-3-ketobutyrate) and ketogenic (can yield acetyl-CoA via the threonine dehydrogenase pathway). It contributes to one-carbon metabolism through its conversion to glycine and downstream methyl-group transfer, intersecting with folate-dependent biosynthesis of nucleotides.

Connective tissue building block. Threonine residues are incorporated into collagen and elastin, with bound carbohydrate at threonine positions contributing to the glycoprotein architecture of skin, tendon, and bone matrix. Adequate threonine is necessary — though not sufficient — for normal connective tissue turnover.

Signaling roles: TOR and MAPK pathways. Tang and colleagues (2021) summarize evidence that threonine availability modulates the mTOR (mechanistic target of rapamycin, a central protein kinase that integrates nutrient signals to control cell growth and protein synthesis) pathway and the MAPK signaling cascade, with implications for cell proliferation and intestinal immune function. Most direct evidence is from animal and cell models.

Ferroptosis modulation (animal data). Kim and colleagues (2022) report in Caenorhabditis elegans that L-Threonine supplementation extends healthspan by elevating ferritin (the cellular iron-storage protein) expression and inhibiting ferroptosis (a form of regulated cell death driven by iron-dependent lipid peroxidation), an effect operating through the DAF-16 and HSF-1 longevity pathways (worm orthologs of FOXO and heat-shock factor signaling). This mechanism is the basis for the longevity-relevant interest in L-Threonine but has not been demonstrated in mammals.

Pharmacokinetics. Oral L-Threonine is well absorbed from the small intestine through Na⁺-dependent neutral-amino-acid transport. Plasma concentrations rise within 1–2 hours of ingestion. The Matsumoto 2025 safety trial in healthy adult men (industry-funded; conducted by Ajinomoto Co. Inc., a major industrial L-Threonine fermentation producer with a direct financial interest in the supplement market) reported dose-dependent increases in plasma threonine and its metabolite L-2-aminobutyrate at supplemental intakes of 6, 9, and 12 g/day, with no consistent perturbation of other amino acid pools. Plasma half-life of free threonine is short (on the order of hours), and tissue uptake follows competitive transport across the blood-brain and intestinal barriers. Hepatic metabolism via threonine dehydrogenase and threonine aldolase generates glycine and acetyl-CoA; renal excretion of unchanged threonine is minimal under normal conditions. CYP (cytochrome P450, the family of liver enzymes that metabolize most drugs) -mediated metabolism is not relevant.

Selectivity and tissue distribution. L-Threonine is non-selective in the sense that it is incorporated into general protein synthesis everywhere; however, gut goblet cells (the mucin-producing epithelial cells) and rapidly proliferating tissues are the highest-demand sinks.

Where mechanisms compete. The Hauser 1992 MS trial reported that despite elevated cerebrospinal-fluid threonine on supplementation, glycine levels did not change, complicating the simple “threonine raises glycine” model and suggesting that any antispastic effect operates through more localized synaptic dynamics or non-glycinergic mechanisms. The ferroptosis and TOR-pathway findings are mechanistically attractive but remain unverified in humans.

Historical Context & Evolution

L-Threonine was the last of the nine essential amino acids to be discovered, isolated by William Cumming Rose in 1935 from fibrin hydrolysates. Its recognition as essential closed the canonical list of nine essential amino acids and established the framework for protein-quality scoring still used today. Industrial fermentation production of L-Threonine via Escherichia coli and Corynebacterium glutamicum began at scale in the 1980s, primarily for animal-feed supplementation in swine and poultry where threonine is the second- or third-limiting amino acid.

Therapeutic interest in human supplementation traces to the late 1980s and early 1990s, when the rationale that elevating threonine could enhance glycinergic neurotransmission led to small antispasticity trials. The Hauser 1992 MS trial (26 patients, 7.5 g/day) found measurable but non-symptomatic improvement on clinical examination; the Lee 1993 trial (33 patients, 6 g/day, spinal spasticity) reported a modest positive effect. Larger replication did not follow, and the 2002 Paisley systematic review and the 2017 Cochrane ALS overview both concluded that the evidence does not support a clinically useful effect for spasticity.

Through the 1990s and 2000s, threonine research shifted toward animal nutrition (pig and poultry growth performance and gut health) and away from human therapeutic trials. The 2010s produced the body of work establishing threonine’s central role in mucin synthesis and intestinal barrier function, with reviews (Tang 2021) consolidating the picture.

The most recent decade has reopened a longevity-research thread: the Kim 2022 Nature Communications paper showed that L-Threonine is elevated in C. elegans under dietary restriction and that supplementation extends nematode healthspan via ferritin-dependent ferroptosis inhibition. This created a wave of speculative consumer interest in threonine as a “longevity amino acid,” although mammalian and human translation has not been demonstrated. The Matsumoto 2025 randomized double-blind crossover safety trial established a NOAEL (no-observed-adverse-effect level, the highest dose at which no harmful effect is observed) of 12 g/day in healthy adult men, providing the first modern systematic safety assessment of supraphysiological intakes in humans. The active NCT06225648 trial in adults over 60 is now revisiting the threonine-requirement question for older adults specifically, motivated by mucin-barrier decline with age. The currently active questions are whether mucin-barrier-targeted supplementation can be validated in older adults, whether the worm ferroptosis findings generalize to mammals, and whether any chronic safety signal emerges beyond 12 weeks.

Expected Benefits

A dedicated search for L-Threonine’s complete benefit profile was conducted across systematic reviews, narrative reviews, integrative-medicine sources, the C. elegans longevity literature, and specialty supplement references prior to drafting this section.

High 🟩 🟩 🟩

No benefits at this evidence level have been documented for L-Threonine supplementation in healthy adults beyond meeting baseline dietary requirements; the controlled-human-trial base remains thin.

Medium 🟩 🟩

Modest Reduction in Spinal Spasticity ⚠️ Conflicted

Oral L-Threonine at 6–7.5 g/day reduces clinical signs of spasticity (Ashworth Scale-measured muscle tone) in patients with multiple sclerosis or spinal-cord-related spasticity. The mechanism is hypothesized to involve enhanced glycinergic inhibition in the spinal motor reflex arc. The Hauser 1992 MS RCT and the Lee 1993 spinal-spasticity RCT both reported small statistically detectable benefits; however, the 2002 Paisley systematic review and the 2017 Cochrane overview classify the evidence as insufficient for routine clinical recommendation, and replication in larger trials is absent. The benefit is modest and subjective improvements were not consistently noted by patients or physicians in the Hauser trial.

Magnitude: Small reductions in Ashworth score (approximately 10% threshold for “responder” classification in the Lee trial); functional-status changes not consistently demonstrated.

Low 🟩

Support for Intestinal Mucin Synthesis and Gut Barrier Function

L-Threonine is a high-percentage constituent of intestinal mucin, and 40–60% of dietary threonine is consumed by the gut on first pass for mucin output. Animal studies (rodent, piglet) show that threonine restriction reduces mucin synthesis and increases intestinal permeability, while supplementation supports goblet-cell output. Direct controlled human data on supplemental threonine specifically improving mucin synthesis or intestinal permeability are very limited; the active NCT06225648 trial in adults over 60 is examining threonine requirements for mucin-barrier maintenance with aging.

Magnitude: Not quantified in available studies.

Glycine Precursor Effects on Inhibitory Tone

L-Threonine can be converted to glycine, which acts as the primary inhibitory neurotransmitter of the spinal cord and contributes to GABAergic (relating to GABA — gamma-aminobutyric acid, the main inhibitory neurotransmitter in the brain) -like calming effects supraspinally. Practitioner sources (Will Cole, Josh Axe) cite anecdotal effects on mood and stress modulation through this pathway. Direct controlled human trials of supplemental threonine specifically for anxiety, mood, or sleep are absent; the Hauser MS trial notably reported elevated CSF (cerebrospinal fluid) threonine without elevated glycine, complicating the simple precursor mechanism.

Magnitude: Not quantified in available studies.

Connective Tissue Substrate Provision

Threonine is incorporated into collagen and elastin, contributing to the structural matrix of skin, tendon, ligament, and bone. Adequate threonine intake is necessary for normal connective tissue synthesis and wound healing. Whether supplemental intake above dietary adequacy provides additional benefit for skin, joint, or bone outcomes has not been tested in controlled human trials.

Magnitude: Not quantified in available studies.

Speculative 🟨

Healthspan Extension via Ferroptosis Inhibition

The Kim 2022 Nature Communications report in C. elegans found that L-Threonine supplementation extends nematode healthspan and lifespan (approximately 18% maximal lifespan extension at 200 μM in worms) by elevating ferritin and inhibiting ferroptosis through DAF-16 and HSF-1 (worm orthologs of FOXO and heat-shock factor longevity pathways). The mechanism is mechanistically intriguing for human longevity but has not been demonstrated in mammals or humans. Inclusion here reflects mechanistic plausibility from a single high-impact invertebrate study only.

Adjunct in Amyotrophic Lateral Sclerosis Cramps

Threonine has been studied as a candidate for ALS-related cramps and spasticity. The 2017 Cochrane ALS overview classifies the evidence as uncertain due to very low quality or non-reported numerical data, and oral threonine does not appear to slow disease progression. Inclusion here reflects historical research interest rather than positive controlled-trial outcome data.

Mood and Anxiety Support via Glycine Conversion

Practitioner sources frequently cite threonine’s potential to support mood and anxiety regulation through brain glycine elevation. Direct controlled trials of L-Threonine for depression, anxiety, or sleep outcomes in healthy adults are essentially absent. Inclusion here reflects the proposed precursor mechanism rather than positive clinical evidence.

Skin and Connective Tissue Outcomes

Marketing for L-Threonine supplements often references collagen and elastin synthesis. Direct controlled trials of supplemental L-Threonine for skin elasticity, wound healing, or joint outcomes are not available; baseline dietary adequacy from typical Western or Asian protein intake appears to meet this need.

Immune Function Support

L-Threonine contributes to immunoglobulin synthesis (immunoglobulins contain notable threonine residues) and to MAPK and TOR signaling in immune cells (Tang 2021). Direct controlled human trials of supplemental L-Threonine for clinically meaningful immune outcomes are absent.

Benefit-Modifying Factors

Genetic considerations: No common pharmacogenomic variants are established as clinically meaningful modifiers of L-Threonine response. Variants affecting the LNAA transporter or threonine dehydrogenase activity have been described biochemically but lack outcome studies in supplementation contexts. PKU (phenylketonuria, an inherited disorder of phenylalanine metabolism) and other inborn errors of amino acid metabolism are clinically relevant in their own right but do not specifically alter threonine handling.
Baseline biomarker levels: Plasma threonine levels are not routinely measured outside research settings; baseline adequacy is typically assumed in well-fed populations. Individuals with low protein intake (vegan or vegetarian diets with limited protein variety, malabsorption, recovery from severe illness, or critical-care contexts) may have lower baseline status, where supplementation might plausibly produce more measurable effects.
Sex differences: Most controlled trials of supplemental L-Threonine — especially the Hauser 1992 MS trial and the Lee 1993 spasticity trial — enrolled mixed-sex cohorts. The Matsumoto 2025 NOAEL safety trial enrolled only adult men, leaving sex-specific safety not directly characterized at the 12 g/day upper bound.
Pre-existing health conditions: Multiple sclerosis with spinal spasticity and spinal-cord injury or disease with spasticity are the conditions in which any signal-to-noise has been most favorable. Inflammatory bowel disease, environmental enteric dysfunction, and conditions with compromised mucin-barrier function are the populations in which the gut-mucin rationale is strongest, although direct supplementation trials are limited.
Age-related considerations: The active NCT06225648 trial in adults over 60 is investigating whether threonine requirements rise with age because of mucin-barrier decline. Older adults at the high end of the longevity audience may have proportionally higher requirements for maintaining intestinal barrier integrity, but this has not yet been quantified.
Form of supplementation: Pure L-enantiomer is biologically active; D-threonine is biologically inactive and not used in human supplements. Crystalline L-Threonine powder, capsules, and tablets are pharmacokinetically similar; specialized “buffered” or “enhanced” formulations have no demonstrated additional benefit.
Dietary protein adequacy: The benefit of supplemental L-Threonine above dietary adequacy is uncertain in healthy adults consuming typical Western or Asian protein intakes (which deliver several grams of threonine per day from food). Supplementation rationale strengthens primarily where dietary intake is low or where targeted gut-mucin or spasticity contexts apply.

Potential Risks & Side Effects

A dedicated search for the L-Threonine safety profile was conducted across drug-reference sources (Mayo Clinic, drugs.com, NIH MedlinePlus), the published trial literature, the 2025 Matsumoto NOAEL safety trial, and consumer-supplement safety summaries prior to this section.

High 🟥 🟥 🟥

No risks at this evidence level have been documented for L-Threonine supplementation; the safety profile is notably benign at studied doses up to 12 g/day in healthy adults for short-term use.

Medium 🟥 🟥

No risks at this evidence level have been documented for L-Threonine supplementation in healthy adults at typical supplemental doses.

Low 🟥

Mild Gastrointestinal Effects

Stomach upset, mild nausea, and abdominal discomfort have been reported with L-Threonine supplementation, particularly at higher doses (≥3 g/day) and on an empty stomach. Effects typically resolve with dose reduction or co-administration with food. Mechanism is presumed to involve high luminal concentrations of free amino acid and osmotic effects.

Magnitude: Not quantified in available studies.

Headache

Headache has been reported with L-Threonine supplementation in some subjects, typically at supplemental intakes of 2 g/day or higher. Effects are generally mild and self-limited.

Magnitude: Not quantified in available studies.

Skin Rash

Skin rash has been reported in some users of L-Threonine supplements per consumer-safety reference sources (WebMD, RxList). The mechanism is not well characterized; the reaction may reflect idiosyncratic hypersensitivity rather than a class effect.

Magnitude: Not quantified in available studies.

Transient Mild Liver-Enzyme and Creatine-Kinase Elevation at High Doses

The Matsumoto 2025 randomized crossover safety trial in healthy men reported a non-specific minor increase in plasma AST (aspartate aminotransferase, a liver enzyme released into blood when liver or muscle cells are damaged) and CK (creatine kinase, an enzyme elevated in blood with muscle injury or strain) at the 9 g/day dose, but notably not at the 12 g/day dose, suggesting a non-monotonic finding without a clear dose-response signal. Anthropometric and other biochemical parameters were unaffected.

Magnitude: Minor elevations within or near normal reference ranges; no clinical events; finding non-monotonic across the dose range.

Speculative 🟨

Long-Term Effects Beyond 4–12 Weeks

The longest controlled human trials of supplemental L-Threonine span 4 weeks (Matsumoto safety trial), 8 weeks (spasticity trials), and up to 12 weeks (subset of clinical observations). Effects of chronic daily supraphysiological L-Threonine intake on amino acid balance, hepatic threonine catabolism enzyme adaptation, and intestinal flora composition over months to years have not been directly characterized.

Effects in Pregnancy and Lactation

Direct trial data on supplemental L-Threonine in pregnancy and lactation are essentially absent. Dietary threonine adequacy is well-recognized as necessary for fetal and infant protein synthesis, but supplemental intake above dietary requirements during these life stages is not supported by safety data.

Theoretical Effects in Renal or Hepatic Insufficiency

Severe renal or hepatic insufficiency may reduce capacity to handle supraphysiological amino-acid loads. Specific dose-adjustment guidance for L-Threonine in these populations is lacking; conservative dosing and clinician supervision are appropriate.

Drug-Metabolism Interactions

L-Threonine is not a significant CYP substrate or inducer; theoretical interactions are limited to the LNAA transporter (potential competition with L-tyrosine, L-tryptophan, and the branched-chain amino acids for blood-brain barrier transit) and to mechanistic overlap with antispastic medications. No clinically significant interactions have been reported in trial literature at standard supplemental doses.

Risk-Modifying Factors

Genetic considerations: No common pharmacogenomic variants are established as clinically meaningful for L-Threonine safety. Inborn errors of amino acid metabolism (rare; typically diagnosed in infancy) require individualized dietary management and supplementation only under specialist supervision.
Baseline biomarker levels: Markedly low baseline protein status, severe hypoalbuminemia, or markedly elevated baseline liver enzymes warrant clinician oversight before initiating supplemental amino acid loads. The 2025 Matsumoto trial enrolled healthy men with normal baseline status; risk profile in compromised populations is not directly known.
Sex differences: The Matsumoto 2025 NOAEL trial enrolled only adult men; sex-specific tolerance and pharmacokinetics at supraphysiological intakes have not been directly quantified. Smaller body weight in women may translate to slightly higher mg/kg exposure at fixed doses, suggesting conservative dose selection.
Pre-existing health conditions: Severe renal insufficiency (CKD (chronic kidney disease, progressive loss of kidney function) Stage 4–5), cirrhosis, urea cycle disorders, and inborn errors of amino acid metabolism shift the benefit-risk balance toward caution. Active gastrointestinal inflammation may either increase threonine needs (mucin demand) or amplify GI side effects of high-dose supplementation; clinical context determines which applies.
Age-related considerations: Older adults (60+) may have reduced gut and hepatic capacity for processing supraphysiological amino-acid loads; lower starting doses (500 mg–1 g) and slower titration are appropriate. Older adults are also the population in whom mucin-barrier maintenance may be most relevant; the active NCT06225648 trial is investigating threonine requirements specifically in adults over 60.
Concurrent antispastic or sedative use: Theoretical additive effects of L-Threonine with baclofen, tizanidine, benzodiazepines, or gabapentinoids on glycinergic and GABAergic tone have not been clinically demonstrated but warrant monitoring at higher supplemental doses.
Pregnancy and lactation: Insufficient safety data; supraphysiological supplementation is generally avoided.

Key Interactions & Contraindications

Antispastic medications (baclofen; tizanidine; dantrolene; benzodiazepines such as diazepam, clonazepam; gabapentinoids such as gabapentin and pregabalin): theoretical additive effect on inhibitory motor tone via shared glycinergic and GABAergic substrate. Severity: monitor; clinically significant interactions have not been reported in trial literature at standard supplemental doses.
Sedatives and hypnotics (benzodiazepines such as alprazolam, lorazepam; “Z-drugs” such as zolpidem; sedating antihistamines such as diphenhydramine): theoretical additive sedation through enhanced glycinergic tone. Severity: caution; clinical relevance unclear at typical supplemental doses.
MAOIs (monoamine oxidase inhibitors, antidepressants that block the enzyme breaking down monoamine neurotransmitters) (e.g., phenelzine, tranylcypromine, selegiline): theoretical interaction through amino acid metabolism overlap. Severity: monitor; specific clinical events have not been reported.
Levodopa (L-DOPA, the dopamine precursor used in Parkinson’s disease) and other LNAA-transported drugs: competition for the LNAA transporter at the blood-brain barrier may modestly reduce drug brain entry if administered simultaneously. Severity: monitor; separate dosing by 1–2 hours where relevant.
Antidiabetic medications (insulin; sulfonylureas such as glipizide; SGLT2 inhibitors (sodium-glucose cotransporter 2 inhibitors, drugs that lower blood sugar by increasing glucose excretion in urine) such as empagliflozin; metformin): no major interaction signal; large amino acid loads may transiently affect glucose dynamics through gluconeogenic substrate provision. Severity: monitor in tightly controlled diabetes.
Other intervention interactions: Fasting and very-low-protein diets — supplemental L-Threonine could partially offset a fasting-induced reduction in mTOR activation; this is mechanistically relevant for those using fasting or protein restriction as longevity strategies and warrants consideration of timing.
Over-the-counter medications (OTC, available without a prescription; OTC sleep aids such as diphenhydramine and doxylamine): theoretical additive sedation through glycinergic/GABAergic overlap. Severity: minor; clinical relevance unclear.
Supplement interactions: Other free amino acids competing for the LNAA transporter — L-tyrosine, L-tryptophan, L-phenylalanine, L-leucine, L-isoleucine, L-valine, L-methionine, and L-Theanine — can reduce each other’s brain entry when co-administered at high free-amino-acid doses. Total free-amino-acid loads should be considered when stacking multiple amino acid supplements.
Supplements with additive effects: Glycine itself (additive on glycinergic substrate); GABA (additive inhibitory tone); magnesium glycinate at high doses (shared glycinergic pathway); L-serine (shared one-carbon and glycine-precursor pool).
Other interventions: Resistance exercise — protein and individual amino acid supplementation timing around training can affect mTOR activation; supplemental L-Threonine alone is not anabolic but contributes to total essential amino acid availability.
Populations to avoid or use with caution: severe renal insufficiency (CKD Stage 4–5; eGFR (estimated glomerular filtration rate, a measure of kidney function) <30 mL/min/1.73m²); cirrhosis (Child-Pugh Class B or C); urea cycle disorders; inborn errors of amino acid metabolism; pregnancy and lactation (insufficient safety data); active severe inflammatory bowel disease (relative caution; potential for both benefit and irritation). There is no absolute contraindication established at typical supplement doses (500 mg–2 g/day) for healthy adults.

Risk Mitigation Strategies

Start at a conservative dose (500 mg–1 g/day) before escalating: the dose-response for any human-relevant supplementation outcome is undefined; higher doses do not have demonstrated incremental benefit and may amplify GI side effects. Mitigates: gastrointestinal effects, headache.
Take with food: co-administration with a meal reduces osmotic and luminal-concentration effects that drive most GI complaints. Mitigates: nausea, abdominal discomfort, mild gastrointestinal upset.
Limit chronic high-dose use without periodic reassessment: the longest rigorous human safety data extend to 4 weeks at 12 g/day (Matsumoto 2025); reassess every 4–8 weeks for continued benefit and adverse effects, and revert to dietary adequacy if no clear benefit accrues. Mitigates: cumulative or adaptive effects not captured in short-term trials.
Verify L-enantiomer purity from reputable suppliers: D-threonine is biologically inactive and racemic mixtures are nutritionally inferior; products carrying USP or third-party-tested certification provide assurance. Mitigates: variable response or under-dosing from low-quality product.
Check liver enzymes and CK if using >6 g/day for more than 2 weeks: the Matsumoto 2025 trial reported transient mild AST and CK elevations at 9 g/day; baseline and follow-up CMP (comprehensive metabolic panel, a routine blood test covering electrolytes, kidney, and liver markers) at 4 weeks is appropriate at supraphysiological doses. Mitigates: detection of any clinically meaningful enzyme elevation.
Avoid stacking multiple high-dose free amino acid supplements without a rationale: combined LNAA loads compete for transporter capacity and can blunt central effects of individual supplements; rotate or time-separate amino acid supplements where central effects are sought. Mitigates: blunted central nervous system effects, unintended interactions.
Coordinate with prescriber if used in established neurological care: spasticity, ALS, MS, and other neurological conditions are settings where supplemental L-Threonine has been studied but where benefit is uncertain and clinician supervision is appropriate. Mitigates: drug-interaction surprises and disease-management drift.
Avoid in pregnancy, lactation, and severe organ insufficiency without clinician oversight: absent safety data warrant precaution rather than routine use. Mitigates: unknown developmental and metabolic risks.
Reassess dietary adequacy first: a typical 70-kg adult needs roughly 1 g of dietary threonine per day, easily provided by 60–80 g of mixed dietary protein. Most longevity-oriented adults already meet baseline needs from food; supplementation should be considered only when a specific use case applies. Mitigates: unnecessary supplementation, opportunity cost relative to dietary protein optimization.

Therapeutic Protocol

L-Threonine supplementation does not have a single standard protocol for healthspan or longevity outcomes; the following reflects the dose ranges studied in the relevant literature and observed in practitioner use.

Baseline-adequacy maintenance dosing: 500 mg–1 g/day, taken with a meal, is sufficient to top up dietary intake in those with low-protein diets (vegan/vegetarian with limited variety, malabsorption, recovery from illness). The WHO/FAO/UNU adult requirement of approximately 15 mg/kg/day (about 1 g for a 70-kg adult) is typically met from food; supplementation in this range is conservative.
Gut-mucin-support dosing: 1–2 g/day, taken with meals, for those targeting intestinal-barrier or mucin-related goals. This range is supported by mechanistic and animal data but not by human controlled-trial outcome evidence; the active NCT06225648 trial in adults over 60 may help define appropriate ranges for older adults.
Spasticity-protocol dosing (clinical use only): 6–7.5 g/day in divided doses (e.g., 2–2.5 g three times daily), based on Hauser 1992 (7.5 g/day) and Lee 1993 (6 g/day); should be supervised by neurologist in established MS or spinal-spasticity care. Benefit is modest and inconsistent across systematic reviews; not recommended as monotherapy.
Best time of day: distributed dosing with meals is standard for amino-acid supplements; no fixed circadian preference is established for L-Threonine. Evening dosing has been proposed for any glycine-conversion-mediated calming effect but is not supported by controlled human trials.
Half-life and dosing strategy: plasma half-life of free L-Threonine is on the order of hours; for sustained tissue exposure, divided dosing (2–3 times daily) is more rational than single large doses, particularly for putative gut-mucin effects where continuous luminal availability is the substrate-limiting factor.
Single vs. split dosing: for low-dose maintenance (≤1 g/day), single daily dosing with the largest meal is sufficient. For doses ≥2 g/day, divided dosing reduces GI side effects and provides more even substrate availability.
Form considerations: crystalline L-Threonine powder and capsules are pharmacokinetically similar; taste of free amino acid powder is mildly sweet to bland and dissolves readily in water. “Buffered” or “enhanced absorption” forms have no demonstrated advantage. Magnesium L-threonate is a different compound (a magnesium salt formulated for cognitive support) and should not be confused with free L-Threonine.
Genetic considerations: no routine genotyping informs L-Threonine dosing in healthy adults; rare inborn errors of amino acid metabolism require specialist management.
Sex-based considerations: clinical effects in women are presumed comparable to those in men, although the 2025 NOAEL trial enrolled only men; conservative starting doses (500 mg–1 g/day) are reasonable for those new to supplementation.
Age considerations: for adults over 60, start at 500 mg–1 g/day with a meal and titrate slowly. Mucin-barrier-supportive intent is strongest in this population, but specific evidence-based ranges remain undefined pending NCT06225648 results.
Baseline biomarkers: dietary protein assessment (24-hour recall or food-frequency review) is the most useful baseline; plasma threonine measurement is not routinely indicated. Liver enzymes and CK at baseline are reasonable for those planning ≥6 g/day for more than 2 weeks.
Pre-existing health conditions: caution and clinician oversight are appropriate in MS, ALS, IBD (inflammatory bowel disease, chronic immune-mediated inflammation of the gastrointestinal tract), severe renal insufficiency, cirrhosis, and inborn errors of amino acid metabolism.

Discontinuation & Cycling

Duration: L-Threonine has been studied in short-term contexts (4–12 weeks) and is best treated as either a defined-duration trial (e.g., 8–12 weeks for a specific mucin or spasticity goal) or a low-dose maintenance addition where dietary intake is inadequate.
Withdrawal effects: no clinically significant withdrawal syndrome has been recognized; abrupt discontinuation is safe.
Tapering protocol: not required at typical supplemental doses; the half-life and pharmacology do not necessitate a taper.
Cycling for tolerance or efficacy: no tolerance pattern or efficacy decay has been documented in controlled trials. No formal cycling protocol has been validated.
Reassessment of indication: if used daily for 8–12 weeks without subjective benefit or measurable change in the targeted outcome (gut-related, motor, or otherwise), discontinue rather than escalating dose; the human controlled-trial base does not support escalation as a default response to non-response.

Sourcing and Quality

Form: pure L-enantiomer is required; D-threonine and racemic mixtures are biologically inactive. Commercially, free L-Threonine is produced primarily by industrial fermentation using Escherichia coli or Corynebacterium glutamicum strains, yielding high-purity L-enantiomer.
Purity and certifications: prefer products with USP, NSF Certified for Sport, Informed-Sport, or independent third-party-testing labels, particularly for athletes subject to drug testing. Pharmaceutical-grade or food-grade specifications (e.g., 99%+ assay) provide the best assurance of purity.
Excipients: L-Threonine is typically blended with minimal excipients in capsule and powder forms; verify against unnecessary fillers, artificial colors, sweeteners, or undisclosed proprietary blends. Pure crystalline powder allows precise dosing without excipient burden.
Reputable brands: brands offering pharmaceutical-grade or third-party-tested L-Threonine include Thorne, Pure Encapsulations, NOW Foods, Jarrow Formulas, Doctor’s Best, BulkSupplements (powder form), and Life Extension (within EAA formulations). No single brand has been highlighted by ConsumerLab in a dedicated L-Threonine review (one does not appear to exist).
Cost benchmark: L-Threonine is inexpensive — typically $0.05–$0.15 per gram from reputable bulk-powder suppliers and $0.20–$0.50 per gram from encapsulated brand-name products. Powders offer substantially better cost efficiency for long-term use; abnormally high prices for “absorption-enhanced” or “stress-relief blend” formulations are not justified by pharmacokinetic evidence.
Distinction from magnesium L-threonate: magnesium L-threonate (Magtein) is a chelated magnesium salt of threonic acid (a metabolite of vitamin C) and is a different compound from L-Threonine itself. The two should not be confused; products marketed for cognition or sleep typically contain magnesium L-threonate, not free L-Threonine.

Practical Considerations

Time to effect: plasma threonine rises within 1–2 hours of oral dosing; meaningful changes in mucin synthesis or other tissue-level outcomes (where supported) develop over days to weeks of continuous availability. Spasticity trials reported clinical changes after 2–8 weeks of consistent dosing. Subjective effects of single doses are generally not reported.
Common pitfalls: confusing L-Threonine with magnesium L-threonate (Magtein) — these are different compounds; expecting strong subjective effects from single doses (the pharmacology supports tissue-level rather than acute CNS (central nervous system, the brain and spinal cord) effects); supplementing without first verifying dietary protein adequacy (which may already meet needs); using doses ≥6 g/day chronically without enzyme monitoring; combining multiple high-dose free amino acids without considering LNAA transporter competition.
Regulatory status: in the United States, L-Threonine is sold as a dietary supplement under DSHEA (the Dietary Supplement Health and Education Act, the U.S. law governing supplement marketing and labeling); GRAS (Generally Recognized As Safe, an FDA designation for substances considered safe under intended food use) status applies to its use in food applications. The FDA (Food and Drug Administration, the U.S. agency that oversees food and drug safety) does not regulate dose or purity for supplements; quality varies, so third-party-tested products are preferred. The EU and most jurisdictions permit L-Threonine in foods and supplements with established safety thresholds.
Cost and accessibility: widely available without prescription at low cost (typically $0.05–$0.50 per gram). No exceptional accessibility issues. Inclusion in nearly all complete-protein dietary sources means standalone supplementation is rarely a nutritional necessity for those eating mixed-protein diets.

Interaction with Foundational Habits

Sleep: Indirect interaction (proposed but not demonstrated). The proposed glycine-conversion mechanism could theoretically support sleep onset given that glycine itself has small evidence for sleep-quality effects at 3 g pre-bed. Direct controlled human trials of L-Threonine for sleep outcomes are absent. In the absence of direct evidence, a small evening dose (1–2 g) may be tested empirically by individuals targeting glycinergic-pathway support, but the response is not supported by trial data.
Nutrition: Direct interaction. L-Threonine shares the LNAA transporter with phenylalanine, tyrosine, leucine, isoleucine, valine, methionine, tryptophan, and L-Theanine. A high-protein meal reduces brain entry of any one supplemental amino acid through transporter competition. For gut-mucin-support intent, taking L-Threonine with meals is rational because the gut is the primary first-pass extraction site. Dietary adequacy from mixed protein sources (60–80 g protein per day delivers approximately 2.5–3.5 g threonine) typically obviates the need for free-amino-acid supplementation in this domain.
Exercise: Indirect interaction. L-Threonine is one of the nine essential amino acids contributing to muscle protein synthesis when EAA pools are limiting; alone it does not have demonstrated anabolic effects equivalent to leucine-rich EAA blends. Resistance training with adequate dietary protein (1.2–2.0 g/kg/day) supplies threonine in amounts well beyond supplemental ranges. For those targeting healthspan with caloric or protein restriction, supplemental L-Threonine could theoretically blunt some fasting-induced reductions in mTOR signaling — relevant context to consider for those using fasting as a longevity strategy.
Stress management: Indirect interaction (proposed but not demonstrated). The glycine-precursor pathway has been cited by practitioner sources as a route to mood and anxiety support, but direct controlled human trials of L-Threonine for stress, anxiety, or cortisol outcomes are absent. Foundational stress-management practices (sleep, breathwork, meditation, physical activity, social connection) have substantially better evidence and should not be displaced by speculative amino-acid supplementation.

Monitoring Protocol & Defining Success

Baseline testing for L-Threonine supplementation in healthy adults at typical doses is minimal; monitoring is more relevant at supraphysiological intakes (>6 g/day for more than 2 weeks) or in those with neurological or gastrointestinal indications.

Ongoing monitoring cadence: dietary protein assessment at baseline; CMP (liver enzymes, kidney function) at baseline and at 4 weeks for supraphysiological doses (≥6 g/day); CK at baseline and at 4 weeks if doses ≥6 g/day; symptom diary (gut symptoms, motor symptoms in clinical use, subjective changes) at baseline, 4 weeks, and 8 weeks; reassess every 8–12 weeks for indication-specific outcomes.

Biomarker	Optimal Functional Range	Why Measure It?	Context/Notes
Dietary protein intake (24-hour recall)	1.2–2.0 g/kg/day for longevity-oriented adults	Establishes baseline threonine adequacy	Conventional RDA (recommended dietary allowance) 0.8 g/kg/day is widely viewed as inadequate for older adults and those targeting muscle preservation; verify before supplementing
Plasma threonine (specialty test)	Within reference range (typically 80–250 µmol/L fasting)	Confirms baseline adequacy in suspected deficiency	Not routinely indicated; specialty amino acid panels available through select labs
AST and ALT	AST <30 U/L, ALT <30 U/L	Detects supraphysiological-dose effect	ALT (alanine aminotransferase, liver enzyme released into blood with hepatocyte injury). Conventional range AST <40, ALT <55; functional medicine targets the lower half. Matsumoto 2025 reported transient minor AST elevation at 9 g/day (not 12 g/day)
Creatine kinase (CK)	30–200 U/L (sex- and activity-dependent)	Detects muscle effects at high doses	Conventional range up to 380 U/L; baseline informed by exercise pattern. Matsumoto 2025 reported transient minor CK elevation at 9 g/day
Comprehensive metabolic panel	All within reference range	General safety screen	Baseline and at 4 weeks for ≥6 g/day; less stringent for typical supplemental doses (<2 g/day)
GI symptom diary	No new or worsening symptoms	Detects mucin or barrier-related changes	Self-report of bowel pattern, stool form (Bristol scale), abdominal comfort; particularly useful for the gut-mucin use case
Modified Ashworth Scale (clinical only)	Pretreatment baseline; response defined as ≥10% reduction	Standard spasticity outcome measure	Clinical use only; under neurologist supervision in MS or spinal spasticity contexts

Qualitative markers to track:

Subjective gut comfort and bowel pattern (relevant for the gut-mucin use case)
Subjective calm or relaxation 30–120 minutes post-dose (relevant for the speculative glycine-conversion use case)
Skin and connective-tissue subjective changes over 8–12 weeks (relevant for the speculative connective-tissue use case)
Motor function changes in MS or spinal spasticity contexts (clinical use only, under supervision)
Any new GI symptoms, headache, or skin reactions (early-warning markers for adverse effects)
General energy and well-being (non-specific but useful for trial-discontinue decisions if no benefit accrues)

Emerging Research

Threonine requirement in older adults: Threonine Requirement in Adults >60 Years of Age (NCT06225648) — a recruiting trial of 40 healthy adults over 60 directly measuring threonine requirements via the indicator-amino-acid-oxidation method, motivated by mucin-barrier decline with age. This trial may help define whether older adults need higher threonine intakes than the current RDA derived from young-adult studies.
Indispensable amino acid supplementation in pediatric environmental enteric dysfunction: The Efficacy of Amino Acid Supplementation in Treating Environmental Enteric Dysfunction Among Children At Risk of Malnutrition (NCT06617130) — a not-yet-recruiting open-label trial of 66 Malawian children (18–36 months) testing whether adding indispensable amino acids (including threonine) to standard complementary food reduces environmental enteric dysfunction; addresses gut-barrier-targeted nutrition with threonine as a key constituent.
Ferroptosis and healthspan in mammals: the Kim et al. 2022 Nature Communications report establishing L-Threonine as a healthspan extender in C. elegans through ferritin-dependent ferroptosis inhibition is the foundation for a research direction that has not yet been tested in mice or humans. Future research areas include rodent dietary-restriction-mimic trials and human plasma-metabolomics studies linking threonine status to age-related ferroptosis markers.
NOAEL safety extension: the Matsumoto et al. 2025 RCT establishing 12 g/day as the no-observed-adverse-effect-level in healthy men provides a foundation for longer-duration and sex-balanced safety trials. Future research areas include 12-week and 6-month studies in mixed-sex cohorts to characterize chronic-dose tolerance and any cumulative metabolic effects.
Long-term safety and chronic-dose effects: the absence of months-to-years controlled data is a significant evidence gap; observational cohorts and 6–12 month RCTs are needed to assess whether chronic supraphysiological L-Threonine supplementation produces measurable effects on hepatic threonine catabolism, intestinal flora composition, glycine metabolism, or amino-acid balance.
Mucin-barrier outcome measurement: future research areas include direct measurement of intestinal permeability biomarkers (e.g., zonulin, lactulose-mannitol ratio) and mucin-thickness imaging in trials of supplemental L-Threonine in adults with subclinical or clinical gut-barrier dysfunction.
MS and spasticity revisitation: the historical small RCTs (Hauser 1992, Lee 1993) and the negative systematic-review conclusions have effectively closed this research line; revival would require either combination protocols or stratification by spasticity phenotype to establish a useful clinical role.

Conclusion

L-Threonine sits at an unusual crossroads of essential nutrient, animal-feed industry workhorse, and speculative longevity candidate. As an essential amino acid, adequate intake is necessary; as a supplement above dietary adequacy, the evidence base for any specific health-and-longevity outcome in humans is thin. The strongest controlled-trial signal — modest reduction in spasticity in multiple-sclerosis and spinal-cord conditions — has not survived systematic-review scrutiny, and replication has been essentially absent. Mechanistically attractive roles in gut mucin synthesis, glycine precursor supply, connective tissue formation, and healthspan-relevant ferroptosis inhibition are supported by animal and cellular data but lack direct human controlled-trial outcome evidence. The most rigorous modern human safety data come from an industry-funded study by a major industrial threonine producer, which is a structural conflict of interest worth weighing when interpreting the favorable safety bound.

The safety profile is favorable at typical supplemental doses; mild gastrointestinal upset, occasional headache, and rare skin rash account for most reported adverse events. No withdrawal syndrome and no major drug-interaction signal are recognized.

For health- and longevity-oriented adults, the overall picture frames L-Threonine as a nutrient first and a supplement second: adequate dietary intake from mixed protein sources typically meets requirements, and any incremental signal from supplementation is confined to narrow contexts where dietary intake is low or specific gut, neurological, or age-related considerations apply.

Top - Benefits - Risks - Protocol

L-Threonine for Health & Longevity

Motivation

Recommended Reading

Grokipedia

Examine

ConsumerLab

Systematic Reviews

Mechanism of Action

Historical Context & Evolution

Expected Benefits

High 🟩 🟩 🟩

Medium 🟩 🟩

Modest Reduction in Spinal Spasticity ⚠️ Conflicted

Low 🟩

Support for Intestinal Mucin Synthesis and Gut Barrier Function

Glycine Precursor Effects on Inhibitory Tone

Connective Tissue Substrate Provision

Speculative 🟨

Healthspan Extension via Ferroptosis Inhibition

Adjunct in Amyotrophic Lateral Sclerosis Cramps

Mood and Anxiety Support via Glycine Conversion

Skin and Connective Tissue Outcomes

Immune Function Support

Benefit-Modifying Factors

Potential Risks & Side Effects

High 🟥 🟥 🟥

Medium 🟥 🟥

Low 🟥

Mild Gastrointestinal Effects

Headache

Skin Rash

Transient Mild Liver-Enzyme and Creatine-Kinase Elevation at High Doses

Speculative 🟨

Long-Term Effects Beyond 4–12 Weeks

Effects in Pregnancy and Lactation

Theoretical Effects in Renal or Hepatic Insufficiency

Drug-Metabolism Interactions

Risk-Modifying Factors

Key Interactions & Contraindications

Risk Mitigation Strategies

Therapeutic Protocol

Discontinuation & Cycling

Sourcing and Quality

Practical Considerations

Interaction with Foundational Habits

Monitoring Protocol & Defining Success

Emerging Research

Conclusion